Biosortia Pharmaceuticals moves its corporate headquarters to biopharma hub in San Diego, California

San Diego, California (January 11, 2016) – Biosortia Pharmaceuticals Inc. announces today that it has been selected by Johnson & Johnson Innovation – JLABS (JLABS) to operate as a resident company within its flagship JLABS facility in San Diego. Biosortia, a leader in drug discovery from unculturable microorganisms for cancer, infectious disease, central nervous system (CNS), and anti-inflammatory therapeutics also announced they will move their corporate headquarters to San Diego, California.

JLABS is an entrepreneurial community designed as a model where scientists can focus on science, permitting Biosortia’s scientific talent to advance the company’s drug pipeline. JLABS resident companies maintain complete entrepreneurial freedom and IP ownership as they focus on scientific innovation. Resident companies are an example of why JLABS is a stepping stone towards commercial success. JLABS’s capital-efficient and flexible platform provide early-stage companies with many of the advantages of being at a big company while preserving an entrepreneur’s equity and freedom to drive their science forward.

Biosortia Pharmaceuticals has research labs in Charleston South Carolina and technology operations in Columbus Ohio and plans on continuing to grow at those locations as the company advances the pipeline and discovery. Ross Youngs, CEO believes “The opportunity to move corporate headquarters and expand in San Diego at this critical juncture in the growth of the company. The connection to the San Diego biopharma cluster will permit Biosortia to accelerate ongoing development efforts as well as the discovery of new compounds for high priority unmet needs and will help build relations with other scientific collaborators, executive leadership, and funding sources.”

Biosortia utilizes proprietary technologies for unprecedented access to a new frontier of natural chemistry that is ideally suited for drug discovery and commercial drug development. Biosortia obtains drug-like metabolites from unculturable aquatic consortia of microorganisms at scale. Aquatic microbial consortia consisting of massive communities of micro-algae, bacteria, and other microorganisms produce a wealth of metabolites for communication and survival with potential applications for human therapeutics.

###

About Biosortia Pharmaceuticals – Biosortia has a proven and unique ability to obtain unculturable aquatic microbial consortia from the natural environment in unprecedented quantities allowing its research team to discover a diverse array of new natural products. Biosortia is actively engaging pharmaceutical research and development organizations to explore the huge opportunity of exploring aquatic microbial consortia for potential therapeutic agents.

About JLABS – The Biosortia Pharmaceutical operations are located at JLABS in San Diego (JLABS @SD). JLABS is a 40,000 square-foot life science innovation center, located in San Diego. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a “no strings attached” model, JJI does not take an equity stake in the companies occupying JLABS and the companies are free to develop products – either on their own or by initiating a separate external partnership with JJI or any other company.